Fluconazole versus itraconazole for resistant ringworm (tinea corporis)
Official title: Comparing the Efficacy of Oral Fluconazole Versus Oral Itraconazole in Treating Resistant Tinea Corporis
Run by Capital Development Authority (CDA) · NCT07342153 · Data updated 2026-11-12
This study will test whether oral fluconazole or oral itraconazole works better to clear persistent tinea corporis in adults who have had the infection for at least six months.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 126 (estimated) |
| Sponsor | Capital Development Authority (CDA) Academic / other |
| Locations | 1 site (Islamabad, Punjab Province) |
| Status | Recruiting |
| Started | November 1, 2025 |
| Main results expected | February 20, 2026 |
| Study ends | March 10, 2026 |
| Registry record updated | January 15, 2026 |
| Trial ID | NCT07342153 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–70 with clinically persistent tinea corporis for ≥6 months despite topical antifungals and KOH confirmation of fungal hyphae are ideal candidates.
✕Probably not a fit
People who recently used oral antifungals, have known immunosuppressive conditions, are pregnant or breastfeeding, or cannot attend the single study site are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, double‑blind trial comparing oral itraconazole 200 mg once daily with oral fluconazole 150 mg every other day for four weeks in adults with resistant tinea corporis. Eligible participants are 18–70 years old with disease lasting at least six months despite topical therapy and KOH-confirmed fungal hyphae. Participants will be enrolled at the Dermatology Department of CDA Hospital, Islamabad and randomly assigned to one of the two treatment arms without knowing which drug they receive. The primary outcome is clinical and mycological clearance following the four‑week treatment period with follow-up for relapse.
Why it matters
Potential benefit: If successful, the trial could identify which commonly used oral antifungal more reliably clears resistant tinea corporis and reduces relapses.
How similar studies have gone: Previous studies show both fluconazole and itraconazole can treat dermatophyte infections, but direct head-to-head data specifically in resistant tinea corporis are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Adults aged 18-70 years Male or female Clinical diagnosis of resistant tinea corporis, defined as persistent disease ≥6 months despite topical antifungal therapy Microscopic confirmation of fungal hyphae on KOH preparation of skin scrapings Exclusion Criteria: Prior use of oral antifungal therapy within the past 3 months Recent antibiotic treatment for superadded bacterial skin infection in the past 1 month Known immunosuppressive conditions (e.g., diabetes mellitus, malignancy) Current or recent use of immunosuppressive drugs Pregnant or lactating women
Where it's running
-
CDA Hospital Islamabad
Islamabad, Punjab Province, Pakistan Recruiting
Study contacts
- Principal investigator: Urooj Fatima, MBBS — Capital Development Authority (CDA)
- Study coordinator: Urooj Fatima, MBBS
- Email: urooj29scorpio@gmail.com
- Phone: +923363005069
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dermatophyte antifungal susceptibility in Faisalabad: terbinafine and itraconazole MICs
This study tests how common skin fungus infections in Faisalabad respond to terbinafine and itraconazole by measuring the lowest drug levels that stop growth in patient samples.
-
MMR vaccine injections into lesions for stubborn ringworm of the body and groin (tinea corporis and cruris)
This pilot will test whether injecting the MMR vaccine into affected skin can help people ages 10–60 with tinea corporis or cruris that hasn't responded to standard antifungal treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.